{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:48:55Z","timestamp":1784843335205,"version":"3.55.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"crossref","award":["2020\/985800-0"],"award-info":[{"award-number":["2020\/985800-0"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-001754"],"award-info":[{"award-number":["INV-001754"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-001754"],"award-info":[{"award-number":["INV-001754"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1084276"],"award-info":[{"award-number":["OPP1084276"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1135288"],"award-info":[{"award-number":["OPP1135288"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Centennial Scholarship Fund"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013638\/1"],"award-info":[{"award-number":["MR\/N013638\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CCF17-7779"],"award-info":[{"award-number":["CCF17-7779"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["218261\/Z\/19\/Z"],"award-info":[{"award-number":["218261\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI147321-01"],"award-info":[{"award-number":["1R01AI147321-01"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA208D-2505B"],"award-info":[{"award-number":["RIA208D-2505B"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Research & Innovation Economic and Social Research Council","award":["ES\/P008011\/1"],"award-info":[{"award-number":["ES\/P008011\/1"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most individuals developing tuberculosis (TB) are working age adults living in low- and middle-income countries (LMICs). The resulting disability and death impact economic productivity and burden health systems. New TB vaccine products may reduce this burden. In this study, we estimated the impact of introducing novel TB vaccines on gross domestic product (GDP) growth in 105 LMICs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We adapted an existing macroeconomic model to simulate country-level GDP trends between 2020 and 2080, comparing scenarios for introduction of hypothetical infant and adolescent\/adult vaccines to a no-new-vaccine counterfactual. We parameterized each scenario using estimates of TB-related mortality, morbidity, and healthcare spending from linked epidemiological and costing models. We assumed vaccines would be introduced between 2028 and 2047 and estimated incremental changes in GDP within each country from introduction to 2080, in 2020 US dollars. We tested the robustness of results to alternative analytic specifications. Both vaccine scenarios produced greater cumulative GDP in the modeled countries over the study period, equivalent to $1.6 (95% uncertainty interval: $0.8, 3.0) trillion for the adolescent\/adult vaccine and $0.2 ($0.1, 0.4) trillion for the infant vaccine. These GDP gains were substantially lagged relative to the time of vaccine introduction, particularly for the infant vaccine. GDP gains resulting from vaccine introduction were concentrated in countries with higher current TB incidence and earlier vaccine introduction. Results were sensitive to secular trends in GDP growth but relatively robust to other analytic assumptions. Uncertain projections of GDP could alter these projections and affect the conclusions drawn by this analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Under a range of assumptions, introducing novel TB vaccines would increase economic growth in LMICs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004252","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T13:33:21Z","timestamp":1689082401000},"page":"e1004252","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-1324","authenticated-orcid":true,"given":"Allison","family":"Portnoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Arcand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-0301","authenticated-orcid":true,"given":"Rebecca A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chathika K.","family":"Weerasuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christinah","family":"Mukandavire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-0944","authenticated-orcid":true,"given":"Roel","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Patouillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebiat","family":"Gebreselassie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Zignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-8255","authenticated-orcid":true,"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-6635","authenticated-orcid":true,"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"pmed.1004252.ref001","unstructured":"World Health Organization. Global Tuberculosis Report 2022 [Online]. Geneva: World Health Organization. 2022 Oct 27 [cited 2022 Oct 27]. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/data."},{"issue":"9979","key":"pmed.1004252.ref002","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO\u2019s new end TB strategy","volume":"385","author":"M Uplekar","year":"2015","journal-title":"Lancet"},{"key":"pmed.1004252.ref003","unstructured":"World Health Organization. The End TB Strategy. Geneva: World Health Organization. 2015 Aug 16 [cited 2021 Jul 1]. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/the-end-tb-strategy."},{"issue":"11","key":"pmed.1004252.ref004","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/21645515.2016.1205769","article-title":"Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines","volume":"12","author":"RC Harris","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"pmed.1004252.ref005","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/joim.13197","article-title":"New tuberculosis vaccines: advances in clinical development and modelling","volume":"288","author":"CK Weerasuriya","year":"2020","journal-title":"J Intern Med"},{"issue":"4","key":"pmed.1004252.ref006","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2214-109X(23)00045-1","article-title":"The impact of alternative delivery strategies for novel tuberculosis vaccines in low- and middle-income countries: a modelling study","volume":"11","author":"RA Clark","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"43","key":"pmed.1004252.ref007","doi-asserted-by":"crossref","first-page":"15520","DOI":"10.1073\/pnas.1404386111","article-title":"Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries","volume":"111","author":"GM Knight","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pmed.1004252.ref008","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41467-020-20731-x","article-title":"Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine","volume":"12","author":"H Fu","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"pmed.1004252.ref009","doi-asserted-by":"crossref","first-page":"e1004155","DOI":"10.1371\/journal.pmed.1004155","article-title":"The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modelling study","volume":"20","author":"A Portnoy","year":"2023","journal-title":"PLoS Med"},{"key":"pmed.1004252.ref010","doi-asserted-by":"crossref","unstructured":"Silva S, Awad S, Abu-Raddad L, Atun R, Goosby E, Reid M. The Health and Economic Benefits Possible with Novel Tuberculosis Vaccines\u2013A Modeling Study in India and Indonesia. rs.3.rs-265017v1. [preprint] 2021 [cited 2023 Jan 9].","DOI":"10.21203\/rs.3.rs-265017\/v1"},{"key":"pmed.1004252.ref011","article-title":"The potential impact of novel tuberculosis vaccines on health equity and financial protection in low- and middle-income countries","author":"A Portnoy","year":"2022","journal-title":"medRxiv"},{"key":"pmed.1004252.ref012","unstructured":"World Health Organization. WHO Global TB Programme (2022). WHO Global TB Database [retrieved from https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/data, 2022 Nov 23]. Geneva, Switzerland: WHO Global TB Programme."},{"issue":"12","key":"pmed.1004252.ref013","doi-asserted-by":"crossref","first-page":"e1679","DOI":"10.1016\/S2214-109X(21)00367-3","article-title":"Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae","volume":"9","author":"NA Menzies","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"3","key":"pmed.1004252.ref014","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/thoraxjnl-2019-213808","article-title":"Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study","volume":"75","author":"J Meghji","year":"2020","journal-title":"Thorax"},{"issue":"Suppl 2","key":"pmed.1004252.ref015","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S2214-109X(15)70088-4","article-title":"Global economic consequences of selected surgical diseases: a modelling study","volume":"3","author":"BC Alkire","year":"2015","journal-title":"Lancet Glob Health"},{"key":"pmed.1004252.ref016","doi-asserted-by":"crossref","first-page":"b4571","DOI":"10.1136\/bmj.b4571","article-title":"The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment","volume":"339","author":"RD Smith","year":"2009","journal-title":"BMJ"},{"issue":"6","key":"pmed.1004252.ref017","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jhealeco.2005.02.003","article-title":"Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance","volume":"24","author":"RD Smith","year":"2005","journal-title":"J Health Econ"},{"issue":"11","key":"pmed.1004252.ref018","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1377\/hlthaff.2019.01701","article-title":"The Macroeconomic Consequences Of Firearm-Related Fatalities In OECD Countries, 2018\u201330: A Value-Of-Lost-Output Analysis","volume":"39","author":"AW Peters","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"pmed.1004252.ref019","doi-asserted-by":"crossref","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","volume":"376","author":"D Husereau","year":"2022","journal-title":"BMJ"},{"key":"pmed.1004252.ref020","unstructured":"World Health Organization. WHO Preferred Product Characteristics for New Tuberculosis Vaccines. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. 2018 Jul 13 [cited 2021 Oct 18]. https:\/\/www.who.int\/publications\/i\/item\/WHO-IVB-18.06."},{"key":"pmed.1004252.ref021","unstructured":"UNICEF. Vaccines pricing data. 2022 Mar 8 [cited 2022 Mar 17]. https:\/\/www.unicef.org\/supply\/vaccines-pricing-data."},{"key":"pmed.1004252.ref022","unstructured":"UNICEF. Costs of Vaccinating a Child. 2020 Aug 14 [cited 2021 Jan 20]. https:\/\/immunizationeconomics.org\/recent-activity\/2021\/6\/15\/standard-costs-of-vaccinating-a-child."},{"key":"pmed.1004252.ref023","unstructured":"Gavi The Vaccine Alliance. GAVI Alliance Vaccine Introduction Grant and Operational Support for Campaigns Policy. Version No. 1.0. Geneva: Gavi, The Vaccine Alliance. 2013 Apr 2 [cited 2018 Jul 12]. www.gavi.org."},{"issue":"9","key":"pmed.1004252.ref024","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40273-020-00930-6","article-title":"Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates","volume":"38","author":"A Portnoy","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"10314","key":"pmed.1004252.ref025","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(21)01591-9","article-title":"Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000\u201317: a financial modelling study","volume":"398","author":"G Ikilezi","year":"2021","journal-title":"Lancet"},{"key":"pmed.1004252.ref026","unstructured":"Global Burden of Disease Collaborative Network. Global HIV\/AIDS Spending 2000\u20132017. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME); 2020 [cited 2022 Jul 28]. https:\/\/doi.org\/10.6069\/0PTH-YJ74"},{"key":"pmed.1004252.ref027","unstructured":"United Nations. World Population Prospects. United Nations Population Division. 2020 [cited 2022 Jul 18]. https:\/\/population.un.org\/wpp\/."},{"key":"pmed.1004252.ref028","unstructured":"Abegunde D, Stanciole A. An estimation of the economic impact of chronic noncommunicable diseases in selected countries. 2006:1\u201321."},{"issue":"6","key":"pmed.1004252.ref029","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1377\/hlthaff.2017.1233","article-title":"The Economic Consequences Of Mortality Amenable To High-Quality Health Care In Low- And Middle-Income Countries","volume":"37","author":"BC Alkire","year":"2018","journal-title":"Health Aff (Millwood)"},{"key":"pmed.1004252.ref030","volume-title":"The Economist Intelligence Unit","author":"N Beaulieu","year":"2009"},{"key":"pmed.1004252.ref031","unstructured":"Bloom DE, Cafiero ET, Jan\u00e9-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, et al. The Global Economic Burden of Non-communicable Diseases. Geneva: World Economic Forum; 2011 [cited 2020 Dec 2]. https:\/\/www.weforum.org\/reports\/global-economic-burden-non-communicable-diseases\/."},{"key":"pmed.1004252.ref032","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jeoa.2014.08.003","article-title":"The macroeconomic impact of non-communicable diseases in China and India: Estimates, projections, and comparisons","volume":"4","author":"DE Bloom","year":"2014","journal-title":"J Econ Ageing"},{"key":"pmed.1004252.ref033","doi-asserted-by":"crossref","unstructured":"Bloom DE, Chen S, Kuhn M, McGovern ME, Oxley L, Prettner K. The economic burden of chronic diseases: estimates and projections for China, Japan and South Korea, NBER working paper 23601; 2017 [cited 2020 Dec 2]. https:\/\/www.nber.org\/papers\/w23601.","DOI":"10.3386\/w23601"},{"key":"pmed.1004252.ref034","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Disability Weights. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME); 2020 [cited 2021 Aug 23]. https:\/\/doi.org\/10.6069\/1W19-VX76"},{"key":"pmed.1004252.ref035","unstructured":"World Health Organization. WHO releases new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB. 2021 Jun 17 [cited 2021 Jul 1]. https:\/\/www.who.int\/news\/item\/17-06-2021-who-releases-new-global-lists-of-high-burden-countries-for-tb-hiv-associated-tb-and-drug-resistant-tb."},{"key":"pmed.1004252.ref036","unstructured":"World Bank. World Bank Country and Lending Groups. Washington, DC: The World Bank; 2021 [cited 2022 Sep 12]. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519."},{"issue":"1","key":"pmed.1004252.ref037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1539-6924.1988.tb01155.x","article-title":"An Investigation of Uncertainty and Sensitivity Analysis Techniques for Computer Models","volume":"8","author":"RL Iman","year":"1988","journal-title":"Risk Anal"},{"key":"pmed.1004252.ref038","unstructured":"Stop TB Partnership. Global Plan to End TB, 2023\u20132030. Geneva: United Nations. 2022 Jul 6 [cited 2022 Nov 23]. https:\/\/www.stoptb.org\/advocate-to-endtb\/global-plan-to-end-tb."},{"key":"pmed.1004252.ref039","doi-asserted-by":"crossref","unstructured":"Portnoy A, Yamanaka T, Nguhiu P, Nishikiori N, Floyd K, Baena IG, et al. Costs incurred by people receiving TB treatment in low- and middle-income countries: a meta-regression analysis. [preprint]. 2023 [cited 2023 Jan 9].","DOI":"10.1016\/S2214-109X(23)00369-8"},{"issue":"10","key":"pmed.1004252.ref040","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S1473-3099(22)00222-5","article-title":"Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial","volume":"22","author":"MF Cotton","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"pmed.1004252.ref041","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final Analysis of a Trial of M72\/AS01(E) Vaccine to Prevent Tuberculosis","volume":"381","author":"DR Tait","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"pmed.1004252.ref042","doi-asserted-by":"crossref","first-page":"e005032","DOI":"10.1136\/bmjgh-2021-005032","article-title":"Assessing vaccine introduction and uptake timelines in Gavi-supported countries: are introduction timelines accelerating across vaccine delivery platforms?","volume":"6","author":"K Luthra","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"1","key":"pmed.1004252.ref043","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1257\/jel.20201642","article-title":"Modern Infectious Diseases: Macroeconomic Impacts and Policy Responses","volume":"60","author":"DE Bloom","year":"2022","journal-title":"J Econ Lit"},{"issue":"8","key":"pmed.1004252.ref044","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/jech-2016-208141","article-title":"Return on investment of public health interventions: a systematic review","volume":"71","author":"R Masters","year":"2017","journal-title":"J Epidemiol Community Health"},{"issue":"Suppl 1","key":"pmed.1004252.ref045","doi-asserted-by":"crossref","first-page":"e000844","DOI":"10.1136\/bmjgh-2018-000844","article-title":"The WHO-INTEGRATE evidence to decision framework version 1.0: integrating WHO norms and values and a complexity perspective","volume":"4","author":"EA Rehfuess","year":"2019","journal-title":"BMJ Glob Health"},{"key":"pmed.1004252.ref046","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12962-020-0203-6","article-title":"Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making","volume":"18","author":"JM Stratil","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"issue":"5","key":"pmed.1004252.ref047","first-page":"629","article-title":"Advancing the WHO-INTEGRATE Framework as a Tool for Evidence-Informed, Deliberative Decision-Making Processes: Exploring the Views of Developers and Users of WHO Guidelines","volume":"11","author":"JM Stratil","year":"2022","journal-title":"Int J Health Policy Manag"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T17:26:50Z","timestamp":1702747610000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004252","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.11.23.22282690","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}